Boryung Corporation stock analysis
Want to see KR:003850 full AI Analyst Report?
Boryung Corporation (003850) Stock Price & Analysis
003850 Stock Chart & Stats
- Day’s Range
- KRW 8,730.00 - KRW 8,870.00
- 52-Week Range
- KRW 7,410.00 - KRW 10,800.00
- Previous Close
- KRW 8,810.00
- Volume
- N/A
- Average Volume (3M)
- 64.72K
- Market Cap
- KRW 744.27B
- Enterprise Value
- KRW 959.75B
- Total Cash (Recent Filing)
- KRW 135.03B
- Total Debt (Recent Filing)
- KRW 388.86B
- Price to Earnings (P/E)
- 10.0
- Beta
- 0.20
- Next Earnings
- Feb 08, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Dec 29, 2026
- Dividend Yield
- 1.82%
Bulls Say, Bears Say
Bulls Say
Revenue Expansion
Sustained multi-year revenue growth indicates expanding commercial activity and continued demand for Boryung’s pharmaceutical portfolio. Steady operating profitability alongside the higher sales base supports ongoing investment in product development, commercialization, and market expansion over the coming quarters.
Cash Conversion
Positive operating and free cash flow show that recent accounting earnings are converting into cash, giving Boryung internal funding for operations, investment, and capital allocation. The strong free-cash-flow-to-net-income relationship also supports financial resilience despite historical year-to-year volatility.
Global Portfolio Expansion
The Kanarb franchise, oncology portfolio, Taxotere rights, China supply agreement, and CDMO contracts broaden Boryung’s commercial reach beyond its established base. These initiatives can diversify revenue sources and strengthen its role in essential medicines and pharmaceutical services.
Bears Say
Gross Margin Compression
The substantial decline in gross margin raises a lasting concern about product mix, pricing power, or cost absorption. If the lower margin profile persists, revenue growth may translate less effectively into operating profit and could constrain reinvestment capacity across the business.
Higher Debt
Although leverage remains moderate and below equity, the recent debt increase reduces financial flexibility if margins remain under pressure or cash generation weakens. Higher obligations can limit capital allocation choices and make the company more sensitive to sustained operating volatility.
Quarterly Profit Volatility
The latest provisional quarter shows that higher sales did not prevent weaker operating profit and a net loss, highlighting uneven earnings conversion. While year-to-date results remained positive, repeated quarterly volatility would make profitability less predictable and complicate planning.
Boryung Corporation News
003850 FAQ
What was Boryung Corporation’s price range in the past 12 months?
What is Boryung Corporation’s market cap?
When is Boryung Corporation’s upcoming earnings report date?
How were Boryung Corporation’s earnings last quarter?
Is Boryung Corporation overvalued?
Does Boryung Corporation pay dividends?
What is Boryung Corporation’s EPS estimate?
How many shares outstanding does Boryung Corporation have?
What happened to Boryung Corporation’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Boryung Corporation?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Boryung Corporation
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Jeong-Gyun Kim
- Employees
- 1,645
- Website
- www.boryung.co.kr
- Address
- Boryeong Building, Seoul, SL, 03127, KR
Boryung Corporation (003850) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 2 | 7 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 10 | 0 | 2 |








